Results 1 to 10 of about 56,967 (294)

The half‐life of amitriptyline. [PDF]

open access: bronzeBritish Journal of Clinical Pharmacology, 1978
PJ Morrison, Howard Rogers, ID Bradbrook
openaire   +5 more sources

European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 1: amitriptyline

open access: yesThe Journal of Headache and Pain, 2023
Objective The aim of this paper is to critically re-appraise the published trials assessing amitriptyline for migraine prophylaxis. Methods We report our methods and results following the Preferred Reporting Items for Systematic Reviews (PRISMA), by ...
C. Lampl   +14 more
semanticscholar   +1 more source

Amitriptyline’s anticholinergic adverse drug reactions–A systematic multiple-indication review and meta-analysis

open access: yesPLoS ONE, 2023
Background Half the US population uses drugs with anticholinergic properties. Their potential harms may outweigh their benefits. Amitriptyline is among the most frequently prescribed anticholinergic medicinal products, is used for multiple indications ...
Maria-Sophie Brueckle   +9 more
semanticscholar   +1 more source

Comparison of Amitriptyline and US Food and Drug Administration–Approved Treatments for Fibromyalgia

open access: yesJAMA Network Open, 2022
This systematic review and network meta-analysis compares amitriptyline with Food and Drug Administration–approved treatments for fibromyalgia related to sleep, fatigue, and health-related quality of life outcomes.
H. M. Farag   +5 more
semanticscholar   +1 more source

The Acid Sphingomyelinase Inhibitor Amitriptyline Ameliorates TNF-α-Induced Endothelial Dysfunction

open access: yesCardiovascular Drugs and Therapy, 2022
Inflammation associated endothelial cell (EC) dysfunction is key to atherosclerotic disease. Recent studies have demonstrated a protective role of amitriptyline in cardiomyocytes induced by hypoxia/reoxygenation.
Yang Ji   +12 more
semanticscholar   +1 more source

Amitriptyline blocks innate immune responses mediated by toll‐like receptor 4 and IL‐1 receptor: Preclinical and clinical evidence in osteoarthritis and gout

open access: yesBritish Journal of Pharmacology, 2021
Osteoarthritis, a major cause of disability in developed countries does not have effective treatment. Activation of TLR4 and innate immune response factors contribute to osteoarthritis progressive cartilage degradation.
E. Franco-Trepat   +9 more
semanticscholar   +1 more source

Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients

open access: yesFrontiers in Pharmacology, 2021
The tricyclic antidepressant amitriptyline is frequently prescribed but its use is limited by its narrow therapeutic range and large variation in pharmacokinetics.
J. Matthaei   +9 more
semanticscholar   +1 more source

Sensitizing TRAIL-resistant A549 lung cancer cells and enhancing TRAIL-induced apoptosis with the antidepressant amitriptyline

open access: yesOncology Report, 2021
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine with the potential to induce cancer cell-specific apoptosis with minimal toxicity to normal cells. Therefore, the resistance of certain cancer cells to TRAIL is a major concern
K. Zinnah, Sang-Youel Park
semanticscholar   +1 more source

Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump

open access: yesmBio, 2020
Efflux pumps of the resistance nodulation-cell division (RND) superfamily are major contributors to multidrug resistance for most of the Gram-negative ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii ...
E. Grimsey   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy